Amarin traded at $15.59 this Friday February 20th, decreasing $0.13 or 0.83 percent since the previous trading session. Looking back, over the last four weeks, Amarin lost 1.96 percent. Over the last 12 months, its price rose by 32.32 percent. Looking ahead, we forecast Amarin to be priced at 15.11 by the end of this quarter and at 13.77 in one year, according to Trading Economics global macro models projections and analysts expectations.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.